“…Exendin-4 (100 nM–5 μM, Tocris, Bristol, UK, Eng et al, 1992; Raufman et al, 1992; Acuna-Goycolea and van den Pol, 2004); NO-donor L-arginine (1 mM, Sigma, St. Louis, MO, USA, Makara et al, 2007; Lameu et al, 2012); GLP-1R antagonist Exendin-3(9–39) (1 μM, Tocris, Eng et al, 1992; Raufman et al, 1992; Acuna-Goycolea and van den Pol, 2004); NOS inhibitor L-NAME (100 μM; Sigma, Makara et al, 2007; Poglia et al, 2011); nNOS inhibitor NPLA (1 μM; Tocris, Chow et al, 2012; Filpa et al, 2015; Gong et al, 2015); CB1 inverse agonist 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl- N -(1-piperidyl) pyrazole-3-carboxamide(AM251; 1 μM; Tocris, Farkas et al, 2010, 2013); G-protein inhibitor GDP-β-S (2 mM; Sigma, Meis et al, 2002; Ponzio and Hatton, 2005; McDermott and Schrader, 2011); NO-scavenger CPTIO (1 mM, Sigma, Makara et al, 2007; Mironov and Langohr, 2007); TRPV1 antagonist 2E-N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-Propenamide (AMG9810; 10 μM; Sigma, Vriens et al, 2011; Liu and Zhuo, 2014; Jian et al, 2016); anandamide-degrading enzyme FAAH inhibitor PF3845 (N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide hydrate; 5 μM; Sigma, Lee et al, 2015). …”